Hanmi Pharmaceutical’s Next-Generation Obesity Drug Named Zantrutide
Hanmi Pharmaceutical has secured an international nonproprietary name (INN) for HM15275, its next-generation obesity drug candidate, which will now be known as zantrutide. The experimental treatment is designed to deliver substantial weight loss while minimizing muscle loss, marking a key component of the company’s strategy to expand its obesity drug pipeline.Hanmi Pharmaceutical, the core…
We haven't written up this one. Korea IT Times has the full story — the link below goes straight to it.
